www.fdanews.com/articles/178557-biologictx-desensitization-data-shows-reduced-time-to-transplant-lower-risk-of-amr-post-transplant
BiologicTx Desensitization Data Shows Reduced Time to Transplant, Lower Risk of AMR Post-Transplant
September 22, 2016
BiologicTx has released positive three-year clinical outcomes data for patients treated with desensitization therapy resulting in a successful transplant.
In all 421 patients, the primary therapeutic modality was IVIg 2g/kg per month infused through BiologicTx therapeutic services in an outpatient setting.
According to clinical results, of 361 patients, 111 have reached transplant, achieving an effective transplant rate of 30.7 percent. — Cynthia Jessup